PROKIDNEY CORP.
No SEC Form 4 filings for $PROK in the last 30 days.
See all $PROK insider activity →PROKIDNEY CORP. (PROK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 prok-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights • Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for antic
ProKidney Corp. (Nasdaq: PROK) appointed Kenneth Locke as Chief Technical Officer, according to a June 2 press release. Locke has 25+ years’ experience in CMC and supply chain, most recently overseeing CMC, Quality and Regulatory at Carisma Therapeutics. The company said the role supports its Phase 3 REGEN-006 (PROACT 1) program and a potential Q2 2027 topline readout.
Control Empresarial and the Slim family have amended their Schedule 13D/A filing for ProKidney Corp., disclosing a beneficial ownership of 73,842,723 shares of Class A common stock, representing 36.0% of the outstanding shares. This increase in holdings is primarily due to an exchange on April 28, 2026, where Control Empresarial converted 63,118,645 Paired Interests and Class B common stock into Class A common stock. The updated ownership percentage is calculated based on a total of 205,061,550 Class A shares outstanding.
Over the past 7 days, alphai's AI scored 1 news story mentioning PROK (PROKIDNEY CORP.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent PROK coverage spans financial news and earnings.
Enrollment completion and updated liquidity and cost trajectory shift the probability-weighted timeline toward the next pivotal readout.
Exec/technical leadership change supports confidence in CMC execution for rilparencel, but no new clinical or regulatory datapoint is provided.
The increased beneficial ownership by Control Empresarial and the Slim family indicates a strategic move that could influence ProKidney Corp.'s stock performance. The conversion of Paired Interests and Class B shares into Class A shares suggests a consolidation of control, potentially signaling confidence in the company's prospects.
ProKidney's positive financial results and clinical updates suggest potential growth and increased investor confidence.
ProKidney's Phase 2 trial results show statistically significant slowing of CKD progression in patients with advanced CKD and diabetes, indicating potential therapeutic efficacy.
alphai scores every news story that mentions PROK with an AI model for sentiment and relevance, and aggregates insider trades from PROKIDNEY CORP.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
PROKIDNEY CORP. (PROK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 prok-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights • Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for antic
6 min readProKidney Corp. (Nasdaq: PROK) appointed Kenneth Locke as Chief Technical Officer, according to a June 2 press release. Locke has 25+ years’ experience in CMC and supply chain, most recently overseeing CMC, Quality and Regulatory at Carisma Therapeutics. The company said the role supports its Phase 3 REGEN-006 (PROACT 1) program and a potential Q2 2027 topline readout.
3 min readControl Empresarial and the Slim family have amended their Schedule 13D/A filing for ProKidney Corp., disclosing a beneficial ownership of 73,842,723 shares of Class A common stock, representing 36.0% of the outstanding shares. This increase in holdings is primarily due to an exchange on April 28, 2026, where Control Empresarial converted 63,118,645 Paired Interests and Class B common stock into Class A common stock. The updated ownership percentage is calculated based on a total of 205,061,550 Class A shares outstanding.
3 min readWINSTON-SALEM, N.C., Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- ProKidney Corp. ( Nasdaq: PROK ) ( "ProKidney" or the "Company" ) , a leading late clinical-stage cell therapy company focused on chronic kidney disease ( CKD ) , today reported financial results for the third quarter ended September 30, ...
3 min readIn patients with advanced chronic kidney disease ( CKD ) and diabetes, treatment with rilparencel resulted in statistically significant and clinically meaningful slowing of CKD progression
3 min readWINSTON-SALEM, N.C., Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- ProKidney Corp. ( Nasdaq: PROK ) ( "ProKidney" or the "Company" ) , a leading late clinical-stage cell therapy company focused on CKD, today presented full results from the Phase 2 REGEN-007 trial evaluating rilparencel in patients with ...
3 min readWINSTON-SALEM, N.C., Oct. 20, 2025 ( GLOBE NEWSWIRE ) -- ProKidney Corp. ( Nasdaq: PROK ) ( "ProKidney" or the "Company" ) , a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease ( CKD ) , today announced that the Company will present two posters, ...
3 min readProKidney ( NASDAQ:PROK ) , a biopharmaceutical company developing cell therapies for chronic kidney disease ( CKD ) , released its second quarter results on August 12, 2025. The main focus of the release was encouraging clinical updates for its lead product rilparencel, especially from the Phase ...
4 min readPROKIDNEY CP (PROK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
2 min readPROK, ROKU and PHAR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 17, 2025.
2 min read
